Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcam-sn-38 + nucleoside analogs + rnai
- Development stage
- Preclinical
- Lead developer
- RNA NanoBiotics
- Modality
- Small Molecules, RNA Therapeutics → Nucleic Acid Therapeutics, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
"epcam-sn-38 + nucleoside analogs + rnai" is a multi-payload RNA nanoparticle therapeutic being developed by RNA NanoBiotics for the treatment of metastatic colorectal cancer (mCRC). The platform utilizes an RNA-based nanoparticle functionalized to target the Epithelial Cell Adhesion Molecule (EpCAM), a protein frequently overexpressed in colorectal tumors. The nanoparticle co-delivers three distinct therapeutic agents: SN-38 (the active metabolite of the topoisomerase I inhibitor irinotecan), nucleoside analogs (which interfere with DNA synthesis), and RNA interference (RNAi) molecules designed to silence specific oncogenic pathways. This combinatorial approach aims to achieve synergistic anti-tumor effects while minimizing systemic toxicity through targeted delivery. The program is currently in preclinical development.
- Other names
- EpCAM-SN-38 + nucleoside analogs + RNAi multi-payload combination
02
Targets
TOP1 (DNA Topoisomerase I)EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on epcam-sn-38 + nucleoside analogs + rnai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcam-sn-38 + nucleoside analogs + rnai.